Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides

ABSTRACT

The invention relates to the compositions of synthetic oligo-β-(1→6)-2-amino-2-deoxy-D-glucopyranosides conjugated to carriers, and methods for making and use same.

RELATED APPLICATIONS

This application claims priority to U.S. provisional applications61/135,493 and 61/208,155, filed on Jul. 21, 2008 and Feb. 20, 2009,respectively, the entire contents of both of which are incorporated byreference herein.

GOVERNMENT SUPPORT

The present invention was supported in part by a grant from the UnitedStates National Institutes of Health RO1AI046706. The U.S. Governmenthas rights in the invention.

FIELD OF THE INVENTION

The invention relates to compositions and methods relating to syntheticoligo-β-(1→6)-2-amino-2-deoxy-D-glucopyranosides which are referred toherein interchangeably as oligo-β-(1→6)-D-glucosamines oroligoglucosamines.

BACKGROUND OF THE INVENTION

Staphylococci are gram-positive bacteria which normally inhabit andcolonize the skin and mucus membranes of humans. If the skin or mucusmembrane becomes damaged during surgery or other trauma, theStaphylococci may gain access to internal tissues causing infection todevelop. If the Staphylococci proliferate locally or enter the lymphaticor blood system, serious infectious complications such as thoseassociated with Staphylococcal bacteremia may result. Thesecomplications include septic shock, endocarditis, arthritis,osteomyelitis, pneumonia, and abscesses in various organs.

Staphylococci include both coagulase-positive organisms that produce afree coagulase and coagulase-negative organisms that do not produce thisfree coagulase. Staphylococcus aureus is the most commoncoagulase-positive form of Staphylococci. S. aureus generally causesinfection at a local site, either extravascular or intravascular, whichultimately may result in bacteremia. S. aureus is also a leading causeof acute osteomyelitis, and causes Staphylococcal pneumonia infections.Additionally, S. aureus is responsible for approximately 1-9% of thecases of bacterial meningitis and 10-15% of brain abscesses.

There are at least thirty-one known species of coagulase-negativeStaphylococci, including S. epidermidis, S. saprophyticus, S. hominis,S. warneri, S. haemolyticus, S. saprophiticus, S. cohnii, S. xylosus, S.simulans, and S. capitis. S. epidermidis is the most frequentinfection-causing agent associated with intravenous access devices, andthe most frequent isolate in primary nosocomial bacteremias. S.epidermidis is also associated with prosthetic valve endocarditis.

Staphylococcus is also a common source of bacterial infection inanimals. For instance, Staphylococcal mastitis is a common problem inruminants such as cattle, sheep, and goats. The disease is generallytreated with antibiotics to reduce the infection but the treatment is acostly procedure and still results in a loss of milk production. Themost effective vaccines identified to date are live, intact S. aureusvaccines administered subcutaneously. The administration of livevaccines, however, is associated with the risk of infection. For thatreason, many researchers have attempted to produce killed S. aureusvaccines and/or to isolate capsular polysaccharides or cell wallcomponents which will induce immunity to S. aureus.

Carrier compounds are sometimes used in vaccines in order to enhance theimmune response to the antigen. For example, the carrier in somevaccines is useful for stimulating T cell help in response to theantigenic moiety. Antigenic moieties that are naturally occurring orfragments of naturally occurring substances are sometime less amenableand less facilely manipulated and/or conjugated to other moieties suchas for example carrier compounds, and this can reduce the therapeuticimpact of such vaccines.

SUMMARY OF THE INVENTION

The invention provides novel methods and compounds for generatingantigenic compositions such as but not limited to vaccines. Inparticular, the invention provides novel methods for modifyingoligosaccharide antigens. These methods involve the controlled synthesisof oligosaccharide (a) comprised of a predetermined order ofmonosaccharide monomers and (b) conjugated to a carrier compound. Theresulting conjugates are better able to stimulate (whether by inductionor enhancement) an immune response to the microbial polysaccharideantigen of interest. As described herein, such immune responses areuseful in the treatment and/or prevention of various infectionsincluding but not limited to Staphylococcal infections.

Various aspects of the invention relate to particular linkers (orlinking agents or spacers or linking reagents, as the terms are usedinterchangeably herein), and their use in synthesizing conjugates. Ofparticular interest are conjugates of oligosaccharides and variouscarrier compounds. These oligosaccharides includeoligo-β-(1→6)-D-glucosamine (linked glucosamine, as referred to herein)which is a comprised of glucosamine monomers attached to each other by aβ-(1→6) linkage. One or more of the various monomers that make up thelinked glucosamine may be N-acetylated. Thus, the monomers may beD-glucosamine or N-acetyl-D-glucosamine monomers, and the linkedglucosamine may comprise a defined order of one or both types of thesemonomers (or monosaccharides, as the terms are used interchangeablyherein). The oligoglucosamines of the invention also comprise spacershaving thiol containing groups on their “reducing” ends. The spacer isused to link the oligoglucosamines to carriers. The carriers may becomprised of amino acids (such as peptides or proteins) although theyare not so limited.

Thus, in one aspect, the invention provides a compound of Formula I

where X is any atom or group, Y is a sulfur blocking group, and n isgreater than 1. In one embodiment, Y is an acyl group. In anotherembodiment, Y is an acetyl group, and the compound has the structure ofFormula II

wherein Ac is an acetyl group.

In still another embodiment, the compound is an activated ester ofFormula I. In another embodiment, the compound is a cyano, azido orhaploid derivative an activated ester of Formula I. In anotherembodiment, the compound has the structure of Formula III

wherein Ac is an acetyl group, and the compound is referred to asN-hydroxysuccinimidyl 4-acetylsulfanyl butyrate. In another embodiment,the compound has the structure of Formula IV

wherein Ac is an acetyl group and the compound is referred to asN-nitrophenyl 4-acetylsulfanyl butyrate.

In another aspect, the invention provides a method for synthesizingN-hydroxysuccinimidyl 4-acetylsulfanyl butyrate (Formula III) comprisingreacting 4-acetylsulfanylbutyric acid (Formula V)

with N-hydroxysuccinimidyl trifluoroacetate (CF₃COOSu) to yieldN-hydroxysuccinimidyl 4-acetylsulfanyl butyrate (Formula III).

In another aspect, the invention provides a method for synthesizingN-nitrophenyl 4-acetylsulfanyl butyrate (IV) comprising reacting4-acetylsulfanylbutyric acid (Formula V)

with N-nitrophenyl trifluoroacetate (CF₃COOpNp) to yield N-nitrophenyl4-acetylsulfanyl butyrate (Formula IV).

In another aspect, the invention provides a method for synthesizing anoligosaccharide conjugated to a carrier comprising reacting anoligosaccharide (a) first with a compound having a structure of FormulaVa or Vb

wherein m is a number selected from 1 to 10, p is a number selected from1 to 20, and R is H or a alkyl group, (b) second with a compound ofFormula I, II, III or IV, and (c) third with a carrier, wherein theoligosaccharide is β-1-6 linked glucosamine.

In yet another aspect, the invention provides a composition comprisingan oligosaccharide bearing an O-linked linker, wherein the linkercomprises

In one embodiment, the oligosaccharide is β-1-6 linked glucosamine. Inanother embodiment, the oligosaccharide is 2-20 monomers in length. Inanother embodiment, the oligonucleotide is 5-11 monomers in length. Instill another embodiment, the oligosaccharide is 7, 9 or 11 monomers inlength.

In one embodiment, the oligosaccharide is 0% acetylated or 100%acetylated. In another embodiment, the oligosaccharide is 0-40%acetylated.

In still another aspect, the invention provides a composition comprisingan oligosaccharide-carrier conjugate comprising an oligosaccharideconjugated to a carrier through a linker that is

wherein the linker is O-linked to the oligosaccharide and N-linked tothe carrier.

In still another aspect, the invention provides a method forsynthesizing an oligosaccharide-carrier conjugate comprising reacting anoligosaccharide conjugated to a linker of Formula IXa or IXb

with a carrier having modified amino group following reaction with acompound of Formula

to yield an oligosaccharide conjugated to a carrier compound through alinker having a structure of Formula VIIIa or VIIIb.

In one embodiment, the carrier is a peptide. In another embodiment, thecarrier is a protein. An example of a carrier is tetanus toxoid.

In one embodiment, the oligosaccharide is β-1-6 linked glucosamine.

In one embodiment, the composition has a oligosaccharide to carrierratio of 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 20:1, 30:1,40:1, 50:1, 60:1, 70:1, 80:1, 90:1 or 100:1.

In some embodiments, the oligosaccharide is 2-20 monomers in length,5-11 monomers in length, or 5, 7, 9 or 11 monomers in length.

In one embodiment, the oligosaccharide is 100% acetylated. In anotherembodiment, the oligosaccharide is 0% acetylated. In still anotherembodiment, the oligosaccharide is 0-40% acetylated.

In some embodiments, the composition further comprises apharmaceutically acceptable carrier, an adjuvant, and/or ananti-bacterial agent.

In another aspect, the invention provides a method for stimulating animmune response in a subject comprising administering to a subject inneed thereof an oligosaccharide-carrier conjugate as described above oran oligosaccharide-carrier conjugate synthesized by a method describedabove in an amount effective to stimulate an immune response in thesubject.

In one embodiment, the subject is a human. In another embodiment, thesubject is non-human.

In another embodiment, the method further comprises isolating antibodiesor antibody-forming cells from the subject.

In another embodiment, the method further comprises administering anadjuvant to the subject. In another embodiment, the method furthercomprises administering an anti-bacterial agent to the subject.

In still another aspect, the invention provides a method for treating orpreventing a infection in a subject comprising administering to asubject having or at risk of developing an infection an effective amountfor inducing an immune response of an oligosaccharide-carrier conjugateas described above or an oligosaccharide-carrier conjugate synthesizedby a method as described above, wherein the infection is caused by abacterial species that makes or is capable of making PNAG.

In one embodiment, the infection is a Staphylococcus infection. In arelated embodiment, the Staphylococcus infection is Staphylococcusaureus infection. In another related embodiment, the Staphylococcusinfection is Staphylococcus epidermidis. In one embodiment, the subjectis at risk of exposure to Staphylococcus. In another embodiment, thesubject has been exposed to Staphylococcus.

In other embodiments, the infection is an E. coli infection, a Y. pestisinfection, a Y. entercolitica infection, a Y. pseudotuberculosisinfection, an Aggregatibacter actinomycetemcomitans infection, anActinobacillus pleuropneumoniae infection, a Bordetella pertussisinfection, a B. parapertussis infection, a B. bronchiseptica infection,an Acinetobacter infection, a Burkholderia infection such asBurkholderia cenocepacia, a Stenatrophomonas maltophilia infection, aShigella infection, or a Klebsiella infection such as Klebsiellapneumoniae.

In some embodiments, the oligosaccharide-carrier conjugate isadministered with an adjuvant and/or an anti-bacterial agent.

In still another aspect, the invention provides a method for producingantibodies comprising administering to a subject an effective amount,for producing antibodies specific for native PNAG, of anoligosaccharide-carrier conjugate as described above or anoligosaccharide-carrier conjugate synthesized by a method as describedabove, and isolating antibodies from the subject.

In another aspect, the invention provides a method for producingmonoclonal antibodies comprising administering to a subject an effectiveamount, for producing antibodies specific for native PNAG, of anoligosaccharide-carrier conjugate as described above or anoligosaccharide-carrier conjugate synthesized by a method as describedabove, harvesting antibody-producing cells from the subject, fusing theantibody-producing cells from the subject to myeloma cells, andharvesting antibody produced from a fusion subclone.

In one embodiment, the antibodies are polyclonal antibodies. In oneembodiment, the subject is a rabbit. In another embodiment, the subjectis a human.

It should be appreciated that all combinations of the foregoing conceptsand additional concepts discussed in greater detail below (provided suchconcepts are not mutually inconsistent) are contemplated as being partof the inventive subject matter disclosed herein. In particular, allcombinations of claimed subject matter appearing at the end of thisdisclosure are contemplated as being part of the inventive subjectmatter disclosed herein. It should also be appreciated that terminologyexplicitly employed herein that also may appear in any disclosureincorporated by reference should be accorded a meaning most consistentwith the particular concepts disclosed herein.

BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1A and B are graphs showing binding of antisera raised tonon-acetylated nona-glucosamine (9GlcNH₂) to PNAG (A) or dPNAG (B) fromS. aureus.

FIGS. 2A and B are graphs showing binding of antisera raise to fullyacetylated nona-glucosamine (9GlcNAc) to PNAG or dPNAG from S. aureus.

FIGS. 3A and B are graphs showing binding of antisera raised toconjugated 9GlcNAc or 9GlcNH₂ to 11GlcNAc or 11GlcNH₂.

FIG. 4 is a graph showing killing of S. aureus strain MN8 bacteria usingan antisera raised in two rabbits, one received the 9GlcNH₂-TT conjugateand the second received the 9GlcNAc-TT conjugate with the antiserumtaken 2 weeks after the last injection of vaccine.

FIG. 5 is a graph showing killing of S. aureus strain MN8 bacteria usingan antisera raised in two rabbits, one of which received the 9GlcNH₂-TTconjugate and the second received the 9GlcNAc-TT conjugate with theantiserum taken 4 weeks after the last injection of vaccine and alsoshows, for comparison, killing of the same bacteria by an antiserumraised to a conjugate vaccine consisting of the dPNAG molecule of ˜100kDa conjugated to tetanus toxoid (TT) and further labeled (051).

FIGS. 6-8 are graphs comparing the killing of S. aureus strains (FIGS. 6and 8, LAC (NT, USA300); FIG. 7, SF8300 (NT, USA300)) by rabbit antisera(bleed 1) to fully acetylated or non-acetylated 9-mer oligoglucosamine(9GlcNH₂) conjugated to TT (9GlcNH₂-TT). For comparison, killing of thesame bacteria by an antiserum raised to a conjugate vaccine consistingof the dPNAG molecule of ˜100 kDa conjugated to tetanus toxoid (TT) andfurther labeled (051).

FIGS. 9-16 are graphs comparing the killing of S. aureus strains (FIG.9, MN8 (capsular polysaccharide (CP) 8); FIG. 10, LAC (non-typable (NT),USA300)); FIG. 11, SF8300 (NT, USA300)); FIG. 12, Newman (CP5); FIG. 13,PS80; FIG. 14, Reynolds (CP5); FIG. 15, Reynolds (non-typable); FIG. 16,Reynolds (CP8)) by a rabbit antiserum (labeled “bleed 2”) to fullyacetylated or non-acetylated 9-mer oligoglucosamine conjugated to TT.For comparison, killing of the same bacteria by an antiserum raised to aconjugate vaccine consisting of the dPNAG molecule of ˜100 kDaconjugated to tetanus toxoid (TT) and further labeled (051).

FIG. 16A is a graph showing the killing of two PNAG-positive (E. coli Jand E. coli P) but not PNAG-negative (E. coli H) E. coli strains byrabbit antisera to 9GlcNH₂-TT obtained 6 weeks after the lastimmunization.

FIGS. 17, 18 and 19 are graphs showing the results of an in vivo studyrelating to prevention of S. aureus skin abscess infection afterimmunization with an antiserum raised to the 9-mer nonacetylatedoligoglucosamine conjugated to TT (9GlcNH₂-TT, bleed 2) and administeredto mice 24 hr prior to infection with 2×10⁴ (FIG. 18), 2×10⁵ (FIG. 19)or 2×10⁶ (FIG. 20) CFU of S. aureus strain LAC.

FIG. 20 is a summary of the results in FIGS. 17-19.

FIGS. 21, 22 and 23 are graphs showing the results of in vivo studiesrelating to prevention of S. aureus abscess infection after immunizationwith an antiserum raised to the 9-mer nonacetylated oligoglucosamine andadministered to mice prior to infection with 1×10⁶ CFU S. aureus MN8(FIG. 21), 4×10⁶ CFU S. aureus Newman (FIGS. 22), and 4×10⁶ CFU S.aureus NewmanΔica and 1.5×10⁶ CFU S. aureus MN8Δica (FIG. 23).

DETAILED DESCRIPTION OF THE INVENTION

The invention relates broadly to the synthesis and use ofoligosaccharide conjugates. The invention provides de novo synthesismethods and the compositions used therein to generate novelcompositions. These synthetic routes facilitate modification of theoligosaccharide or polysaccharide that would not otherwise be possibleusing naturally occurring polysaccharide antigens.

The invention provides inter alia methods for the preparation ofoligo-β-(1→6)-D-glucosamine oligosaccharides or polysaccharides having adefined order of monomers, methods for the conjugation of sucholigosaccharides or polysaccharides to linkers for subsequentconjugation to carrier compounds, methods for the preparation of theoligosaccharide-carrier conjugates or polysaccharide-carrier conjugates,and compositions of these various compounds. The invention furtherrelates to various novel linkers that are unexpectedly more useful thanpreviously known linkers in these preparation methods. The resultantoligosaccharide-carrier conjugates are useful for stimulating an immuneresponse in vivo in human and non-human subjects, including generationof antibodies to the oligosaccharide themselves and the correspondingnaturally occurring PNAG and dPNAG antigens.

PNAG and dPNAG antigens are described in greater detail in published PCTapplication WO 2004/043405. Briefly, PNAG refers to poly N-acetylglucosamine which is a surface polysaccharide made by various bacterialspecies including but not limited to Staphylococci, such as S. aureusand S. epidermis. PNAG exists naturally in both highly and poorlyacetylated forms. A “highly acetylated” form of PNAG is a PNAG havinggreater than 50% acetate substitutions. Poorly acetylated forms of PNAG(referred to herein as dPNAG) may have 0-40% acetylation. (See FormulaVII where R¹ represents the location of the acetyl group, if present.)Native PNAG is a mixture of PNAG forms with varying degrees ofacetylation. Native PNAG may include dPNAG in a mixture with more highlyacetylated forms of PNAG. PNAG or dPNAG may be comprised of hundreds orthousands or more glucosamine units (or monomers).

The oligosaccharides of the invention are intended to mimic regions ofPNAG or dPNAG. Thus, when used in vivo the oligosaccharide-carrierconjugates induce immune responses directed to regions of theoligosaccharide that are similar or identical to PNAG and/or dPNAG andtherefore such immune responses are useful in targeting bacterialspecies that make or are capable of making PNAG and/or dPNAG.

In some aspects of the invention, the oligosaccharides are comprised ofonly D-glucosamine, or only N-acetyl-D-glucosamine units, or apredetermined ratio and order of both types of these monomers. The ratioand order is intended to mimic in some embodiments the ratios and ordersfound in native PNAG. The oligosaccharides are manipulated according tothe invention to comprise a spacer (or a linker, as the terms are usedinterchangeably herein) having a thiol group at its terminus (e.g., itsreducing end).

The preparation of oligosaccharides comprising amine groups, such aslinked glucosamine oligosaccharides (or oligoglucosamines, as the termsare used interchangeably herein) suitable for conjugation to one or morecarriers has proved challenging in the art. This is partly because thestereo-specific synthesis of linked glucosamine requires the use ofparticipating but temporary acyl N-protecting groups (so-called“participating” groups) in the glycosyl donors in order to form thenecessary β-glycoside bond between the monomers. N-phthaloyl,N-trichloroethoxycarbonyl and some other moieties are suitable asparticipating groups. Certain other participating groups however areless suitable including the N-acetyl participating groups that arepresent in some of the oligosaccharides contemplated by the invention.As an example, N-acetylated glycosyl donors are of low reactivity andgive only moderate yields of glycosylation products. In addition, thepresence of N-acetyl groups in glycosyl donor complicates theglycosylation reaction due to oxazoline intermediate formation,migration of N-acetyl groups, and other undesirable chemical reactions.

With regards to linked glucosamines, their structure and moreparticularly the number of amino groups they contain necessitates theintroduction of the linker before total liberation of amino groups.Removal of the above-mentioned temporary N-protecting group to preparefree oligosaccharide is carried out under basic conditions. The mosteffective reagent for removal of an N-phthaloyl participating group ishydrazine hydrate in boiling ethanol. This reagent also effectivelyremoves O-acyl protecting groups including acetyl and benzoyl groupswhich may be contained in the oligosaccharide of interest.

Commercially available linkers that have been used for the attachment ofamino-containing ligands to proteins are pentafluorophenylS-acetylthioglycolate (chemical structure 8 shown in the Examples) andN-hydroxysuccinimidyl 3-acetylsulfanyl-propionate (chemical structure 12shown in the Examples). These linking reagents can be used to introducea thiol moiety into a oligosaccharide; however, as described in greaterdetail in the Examples, both were unstable under the conditions ofremoval of phthaloyl groups. Example 5 shows that a linker based onthioglycolic acid undergoes oxidative rearrangement, and Example 6 showsthat a derivative of 3-mercaptopropionic acid gives a complex mixture ofside products. Both transformations result in loss of the necessarythiol function.

The invention therefore is based in part on the discovery and use of aclass of linkers that is effective and better than previously knownlinkers for conjugating oligosaccharides (including amine containingversions thereof) to a carrier such as a protein. This class of linkersis defined as derivatives of ω-acetylsulfanyl carbonic acid of Formula I(where n>1).

This class of linkers provides effective N-acylation during attachmentto an oligosaccharide. The linker may be an activated ester of Formula Ior its cyano, azido, or haloid derivative. It may be another derivativeof Formula I provided such derivative is active as an acylating agentand thus suitable for attachment to oligosaccharides of the presentinvention. Y represents a temporary blocking group of sulfur atoms,which are known in the art and which include acyl and acetyl groups.Removal of the Y group liberates an SH group which is needed forattachment of the oligosaccharide to the carrier. X represents anyleaving group that provides the necessary acylating ability to thecompound of Formula I.

It is to be understood that any of the linker classes provided by theinvention can be used to conjugate oligosaccharides to carriercompounds. As an example, one linker class may comprise the structure ofFormula II (where n>1):

As another example, another linker class may compriseN-hydroxysuccinimidyl derivatives. An example of such a linker, asdescribed in Examples 1 and 3, is N-hydroxysuccinimidyl 4-acetylsulfanylbutyrate (compound 2 on Scheme 1, Examples 1 and 3). This linker has thestructure of Formula III as follows:

This linker is stable under conditions of total deprotection ofcarbohydrates such as oligosaccharides and polysaccharides.

Another example of an activated ester is N-nitrophenyl 4-acetylsulfanylbutyrate (compound 3, Examples 2 and 3). This compound has the structureof Formula IV as follows:

The invention provides a method for synthesizing N-hydroxysuccinimidyl4-acetylsulfanyl butyrate (Formula III). This method involves reacting4-acetylsulfanylbutyric acid (Formula V)

with N-hydroxysuccinimidyl trifluoroacetate (CF₃COOSu) to yieldN-hydroxysuccinimidyl 4-acetylsulfanyl butyrate (Formula III).

The invention further provides a method for synthesizing N-nitrophenyl4-acetylsulfanyl butyrate (Formula IV). This method involves reacting4-acetylsulfanylbutyric acid (Formula V)

with N-nitrophenyl trifluoroacetate (CF₃COOpNp) to yield N-nitrophenyl4-acetylsulfanyl butyrate (Formula IV).

These synthesis methods are described in greater detail in the Examples.

The invention further provides compositions comprising anoligosaccharide comprising a linker conjugated to the O1-atom of theglucosamine unit at the “reducing end” of the oligosaccharide. ThisO1-conjugated linker is used to attach an SH-containing linker via thereaction with the compound of Formula I. The O1-conjugated linker havethe structure of Formula Va (below) having an aminoalkyl group and wherem may vary from 1 to 10 and R may be H or a simple alkyl group (e.g., amethyl or an ethyl group). Alternatively, an 01-conjugated linker mayhave the structure of Formula Vb (below) where p may vary from 1 to 20and R is the same as in Formula Va.

The oligosaccharides conjugates of the present invention therefore maybe synthesized by coupling the compounds of Formula Va or Vb with thecompound of Formula I. The transformation and subsequent removal of thetemporary S-blocking group (Example 8) or reduction of the correspondingintermediate disulfide (Example 7) results in the generation of a finallinking group used in the conjugation of the oligosaccharides with acarrier compound. Such final linking groups are described in Examples 7and 8 have the structure of Formula VI

The oligosaccharide may comprise 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90 or 100monosaccharide monomers. In some important embodiments, theoligosaccharide comprises 5 or more monomers including 5, 7, 9 or 11monomers. In some embodiments, the oligosaccharide comprises 2-20monomers, or 3-20 monomers, or 4-20 monomers, or 5-20 monomers.

In some important embodiments, the monomer is glucosamine and theoligosaccharide is a linked glucosamine. The structure of a glucosaminemonomer (as present in a linked glucosamine) is as follows:

where R¹ is H in the case of glucosamine units with a “free” aminogroup, or R¹ is an acetyl group (COCH₃) in the case of N-acetylatedglucosamine units. These units are connected through β-(1→6)-linkages.Any number of glucosamine units may be linked, including 2, 3, 4, 5, 6,7, 8, 9, 10, 50, or more units up to 100 units (whether substituted withacetyl groups or unsubstituted).

The degree of N-acetylation in the compounds of Formula VII may vary. Itmay range from 0-50% N-acetylation (i.e., 0-50% of R¹ are acetylgroups), including 0-40% N-acetylation. In some embodiments, the β-(1→6)linked glucosamine is less than 50%, less than 40%, less than 30%, lessthen 20%, less then 10%, or less than 5% N-acetylated. In some importantembodiments, the level of N-acetylation and the position of acetylgroups within an oligosaccharide are known by virtue of the synthesismethod. That is, the oligosaccharide may be synthesized from the orderedarrangement of glucosamine units having or lacking N-acetyl groups. TheExamples provide methods for producing oligosaccharides having definedand ordered acetyl substitutions. In addition, reference can be made toGening et al. Carbohydrate Research 2007 342:567-575, Gening et al.Russian J Bioorganic Chem 2006 32(4):389-399, Yang and Du CarbohydrateResearch 2003 338:495-502, Yang et al. Carbohydrate Research 2003338:1313-1318, and Fridman et al. Organic Letters 2002 4(2):281-283.

The invention still further provides a composition comprising anoligosaccharide-carrier conjugate comprising an oligosaccharideconjugated to a carrier compound through a linker of Formula VIIIa orVIIIb.

wherein the linker is O-linked to the oligosaccharide and N-linked tothe carrier compound.

The invention further provides a method for synthesizing anoligosaccharide-carrier conjugate by reacting oligosaccharide conjugatescomprising SH-terminated linkers such as those having structures ofFormula IXa or IXb

(in the case of compounds from Examples 7 and 8)

with a carrier compound in which terminal amino groups are modified byattachment of a compound of Formula X

to yield an oligosaccharide conjugated to a carrier compound through alinker having a structure of Formula VIIIa or VIIIb.

In some embodiments, a linker of Formula VIIIa or VIIIb is linkedthrough its terminal CH₂-group to the O1-atom of glucosamine unit at the“reducing end” of the oligosaccharide. Such a linkage is considered anO-linkage, and the oligosaccharide is referred to as being O-linked tothe linker.

In some embodiments, a linker of Formula VIIIa or VIIIb is linkedthrough the terminal CO group to an amino group in the carrier compoundby an amide bond. Such a linkage is considered an N-linkage, and thecarrier is referred to as being N-linked to the linker.

Preparation of conjugates of amino-group-containing carrier andoligoglucosamines having an SH-terminated linker, as described above andin Examples 8 and 9, may use the reagent SBAP. The invention howevercontemplates the use of other reagents suitable for linkingamino-group-containing carriers and SH-terminated oligosaccharides(particularly as described by G. Hermanson “Bioconjugate Techniques”,2^(nd) Edition, Academic Press, 2008).

Carrier Compound

A “carrier compound” (or carrier, as the terms are used interchangeablyherein) as used herein is a compound that is conjugated to theoligosaccharide through the use of a linker of the invention. Typically,the carrier compound is one that enhances the immune response to theoligosaccharide ligand.

Carrier compounds include but are not limited to proteins, peptides,polysaccharides, nucleic acids, or other polymers, lipids, and smalloligomeric molecules, particularly the dendrimers. In some embodiments,the carrier compound may be naturally occurring or may be derived from anaturally occurring entity. Proteins include, for example, plasmaproteins such as serum albumin, immunoglobulins, apolipoproteins andtransferrin; bacterial polypeptides such as tetanus toxoid (TT), TRPLE,β-galactosidase, polypeptides such as herpes gD protein, allergens,diphtheria toxoid, salmonella flagellin, hemophilus pilin, hemophilus 15kDa, 28-30 kDa and 40 kDa membrane proteins, Escherichia coli heat labelenterotoxin ltb, cholera toxin, and viral proteins including rotavirusVP and respiratory syncytial virus f and g proteins. The carriers usefulin the invention include any protein that is safe for administration tomammals and optionally that is an immunologically effective carrierprotein. Thus, in some embodiments, the carrier compound may itself beimmunogenic. Examples include compounds that have been used in or asvaccines against a bacterial species such as but not limited to thoselisted herein.

Carrier compounds that are useful particularly for immunization includeproteins such as keyhole limpet hemocyanin, serum albumin, bovinethyroglobulin, or soy bean trypsin inhibitor. Any other compound that isimmunogenic in the species of animal to be immunized can similarly beused.

As shown in the Examples, the oligosaccharide to carrier ratio in theoligosaccharide-carrier conjugates of the invention may vary. Forexample, an oligosaccharide-carrier conjugate may have anoligosaccharide to carrier ratio of 1:1, at least 2:1, at least 3:1, atleast 4:1, at least 5:1, at least 6:1, at least 7:1, at least 8:1, atleast 9:1 or at least 10:1. In still other embodiments, the ratio may beat least 20:1, at least 30:1, at least 40:1, at least 50:1, at least60:1, at least 70:1, at least 80:1, at least 90:1, or greater, up to forexample 100:1 or 700:1 depending on the capacity of carrier compound forattachment of oligosaccharide ligands. As an example, a conjugate thathas an oligosaccharide to carrier ratio of at least 3:1 is a conjugatethat has at least three oligosaccharide moieties attached to a singlecarrier compound.

Utility

The compositions of the invention have a number of in vitro and in vivouses. For example, the compositions of the invention are useful forproducing an antibody response, e.g., as a vaccine for activeimmunization of humans and animals to prevent infection by species ofbacteria that make or are capable of making native PNAG, including butnot limited to Staphylococcus; as a vaccine for immunization of humansor animals to produce anti-dPNAG antibodies that can be administered toother humans or animals to prevent or treat infections by species ofbacteria that make or are capable of making native PNAG, including butnot limited to Staphylococcus; as an antigen to screen for biologicalagents such as monoclonal antibodies capable of preventing infection byspecies of bacteria that make or are capable of making native PNAG,including but not limited to Staphylococcus, libraries of genes involvedin making antibodies, or peptide mimetics; as a diagnostic reagent forinfections by species of bacteria that make or are capable of makingnative PNAG, including but not limited to Staphylococcus; and as adiagnostic reagent for determining the immunologic status of humans oranimals in regard to their susceptibility to infections by species ofbacteria that make or are capable of making native PNAG, including butnot limited to Staphylococcus.

Treatment and Prevention of Infections

The invention provides a method for treating or preventing infection byspecies of bacteria that make or are capable of making native PNAG,including but not limited to Staphylococcus, in a subject comprisingadministering to a subject having or at risk of developing such aninfection an effective amount for inducing an immune response of anoligosaccharide-carrier conjugate of the invention.

Another aspect of the invention provides a method for evaluating theability of a conjugates of the invention to protect against infection byspecies of bacteria that make or are capable of making native PNAG,including but not limited to Staphylococcus, in a subject.

The method involves administering to the subject an effective amount ofthe conjugate, wherein the conjugate induces active immunity, exposingthe subject to bacterial species that make or are capable of makingnative PNAG, and testing for the presence of the bacterial species inthe subject.

The subject may be one that is subject is at risk of exposure to thebacterial species, or one that has been exposed to the bacterialspecies. The conjugate may be administered in a composition togetherwith other agents such as but not limited to one or more adjuvants,and/or one or more anti-bacterial agents, etc.

The infection may be a Staphylococcus infection. The Staphylococcusinfection may a Staphylococcus aureus infection, a Staphylococcusepidermidis infection, but it is not so limited. The infection may be anE. coli infection, a Y. pestis infection, a Y. entercolitica infection,a Y. pseudotuberculosis infection, an Aggregatibacteractinomycetemcomitans infection, an Actinobacillus pleuropneumoniaeinfection, a Bordetella pertussis infection, a B. parapertussisinfection, a B. bronchiseptica infection, an Acinetobacter infectionincluding infection by Acinetibacter complex organisms, a Burkholderiainfection including an infection by Burkholderia complex organisms, aStenatrophomonas maltophilia infection, a Shigella (different species)infection, and a Klebsiella (different species) infection.

The antibodies generated according to the invention may also be used toprevent or treat infection by any infectious or pathogenic microbe thatmakes a molecule that reacts with the antibodies induced by an immuneresponse to the oligosaccharide-carrier conjugate.

An “effective amount for inducing an immune response (e.g., an antibodyresponse)” as used herein is an amount which is sufficient to (i) assistthe subject in producing its own immune protection by e.g. inducing theproduction of antibodies in the subject, inducing the production ofmemory cells, and possibly a cytotoxic lymphocyte reaction etc. and/or(ii) prevent infection from occurring in a subject which is exposed toan infectious or pathogenic microbe that makes or is capable of makingPNAG, including but not limited to Staphylococcus.

In some preferred embodiments, the effective amount of a vaccine forstimulating an immune response is an amount of vaccine that is capableof eliciting the production of antibodies that are cross-reactive withat least two species of Staphylococcus, e.g., S. aureus and S.epidermidis.

One of ordinary skill in the art can assess whether an amount issufficient to induce active immunity by routine methods known in theart. For instance, the ability of a specific conjugate to produceantibody in a mammal can be assessed by screening for antibodies in amouse or other subject using conjugates or their correspondingoligosaccharides.

Subjects as used herein include human and non-human subjects. Non-humansubjects include but are not limited to companion animals such as dogs,cats, ferrets, birds, and the like, agricultural animals such as cows,pigs, goats, sheep, horses, chickens, and the like, zoo animals such asgiraffes, lions, tigers, elephants, bears, and the like, laboratoryanimals such as mice, rats, rabbits, and the like. The subject may be ahuman over 60 years of age. The subject may be one that is healthy.

The subjects to be treated according to the invention includehospitalized patients who are at risk of developing Staphylococcalinfection as a result of exposure to the bacteria in the hospitalenvironment. Particular high risk populations for developing infectionby S. aureus include, for example, renal disease patients on dialysis,and individuals undergoing high risk surgery. High risk populations fordeveloping infection by S. epidermidis also include, for example,patients with indwelling medical devices, such as intravenous lines(e.g., central lines), or prostheses (e.g., hip or knee replacementprostheses), because clinical isolates are often highly adherent toplastic surfaces. In some embodiments, the subject is a subject that hasreceived a medical device implant and in other embodiments, the subjectis one that has not received a medical device implant but may bescheduled to receive one. Subjects at a high risk of developinginfection by S. epidermidis further include, for example, pre-termneonates and patients undergoing chemotherapy. Additional subjects to betreated according to the invention include hospitalized patients orindividuals in the community who become ill and who are at risk ofdeveloping infections with microbes that make or are capable of makingPNAG as a result of exposure to the bacteria in the hospital orcommunity environments.

Immune Response Induction and Antibody Generation

The invention further provides methods for stimulating an immuneresponse in a subject comprising administering to a subject in needthereof an oligosaccharide-carrier conjugate of the invention in anamount effective to stimulate an immune response in the subject. Theimmune response may be an antigen-specific immune response. It may be acellular and/or a humoral immune response. For example, the immuneresponse may result in the production of antibodies and/orantibody-producing cells.

“Passive immunity” as used herein involves the administration ofantibodies to a subject, wherein the antibodies are produced in adifferent subject (including subjects of the same and differentspecies), such that the antibodies attach to the surface of the bacteriaand cause the bacteria to be phagocytosed.

The antibodies generated using the conjugates of the invention may beadministered to any subject at risk of developing an infection by aspecies that makes PNAG or a species that makes another molecule thatreacts with the antibodies to induce passive immunity, and in someembodiments may be particularly suited for subjects incapable ofinducing active immunity. Since vaccination with the antigen might notbe completely effective in high risk immunocompromised subjects, thesesubjects will benefit from treatment with antibody preparations raisedagainst the oligosaccharide-carrier conjugates of the invention toprevent or treat infections such as those due to Staphylococcus aureus.A subject that is incapable of inducing an immune response is animmunocompromised subject (e.g. patient undergoing chemotherapy, AIDSpatient, etc.) or a subject that has not yet developed an immune system(e.g. pre-term neonate).

Thus, the invention provides a method for producing antibodiescomprising administering to a subject an effective amount for producingantibodies specific for the PNAG molecule expressed by an organism suchas Staphylococcus using an oligosaccharide-carrier conjugate of theinvention, and isolating antibodies from the subject. The antibodies maybe polyclonal antibodies. The antibodies may be further modified.

The invention further provides a method for producing monoclonalantibodies comprising administering to a subject an effective amount forproducing antibodies specific for the PNAG molecule using anoligosaccharide-carrier conjugate of the invention, harvestingantibody-producing cells from any tissue containing such cells such asspleen or blood from the subject, fusing the antibody-producing cellsfrom the subject to myeloma cells, and harvesting antibody produced froma fusion subclone.

The invention contemplates the generation of a variety of antibodiesspecific to the oligo-β-(1→6)-D-glucosamines of present invention. Theseinclude chimeric antibodies such as humanized antibodies and antibodyfragments, as well as intact monoclonal and polyclonal antibodies. A“humanized monoclonal antibody” as used herein is a human monoclonalantibody or functionally active fragment thereof having at least humanconstant regions and an antigen binding region (such as 1, 2, 3, 4, 5,or 6 CDRs, or 1 or 2 variable regions, or Fab or F(ab)₂ fragments) froma species other than a human. Humanized monoclonal antibodies, forexample, may be constructed by replacing the non-CDR regions of anon-human mammalian antibody with similar regions of human antibodieswhile retaining the epitopic specificity of the original antibody. Forexample, non-human CDRs and optionally some of the framework regions maybe covalently joined to human FR and/or Fc/pFc′ regions to produce afunctional antibody. European Patent Application 0239400, the entirecontents of which is hereby incorporated by reference, provides anexemplary teaching of the production and use of humanized monoclonalantibodies in which at least the CDR portion of a murine (or othernon-human mammal) antibody is included in the humanized antibody. Thereare entities in the United States which will synthesize humanizedantibodies from specific murine antibody regions commercially, such asProtein Design Labs (Mountain View Calif.), Abgenix, and Medarex.

An intact humanized monoclonal antibody in an isolated form or in apharmaceutical preparation is particularly suited to some aspects of theinvention. Humanized antibodies have particular clinical utility becausethey will not evoke an immune response in humans against the antibodyitself. In one preferred embodiment, a murine CDR is grafted into theframework region of a human antibody to prepare the “humanizedantibody.” See, e.g., L. Riechmann et al., Nature 332, 323 (1988); M. S,Neuberger et al., Nature 314, 268 (1985) and EPA 0 239 400 (publishedSep. 30, 1987).

Human monoclonal antibodies may be made by any of the methods known inthe art, such as those disclosed in U.S. Pat. No. 5,567,610, issued toBorrebaeck et al., U.S. Pat. No. 565,354, issued to Ostberg, U.S. Pat.No. 5,571,893, issued to Baker et al, Kozber, J. Immunol. 133: 3001(1984), Brodeur, et al., Monoclonal Antibody Production Techniques andApplications, p. 51-63 (Marcel Dekker, Inc, new York, 1987), and Boerneret al., J. Immunol., 147: 86-95 (1991).

In addition to the conventional methods for preparing human monoclonalantibodies, such antibodies may also be prepared by immunizingtransgenic animals that are capable of producing human antibodies (e.g.,Jakobovits et al., PNAS USA, 90: 2551 (1993), Jakobovits et al., Nature,362: 255-258 (1993), Bruggermann et al., Year in Immunol., 7:33 (1993)and U.S. Pat. No. 5,569,825 issued to Lonberg).

Human antibodies may also be obtained by recovering antibody-producinglymphocytes from the blood or other tissues of humans. These lymphocytescan be treated to produce cells that grow on their own in the laboratoryunder appropriate culture conditions. The cell cultures can be screenedfor production of antibody to the conjugates of the invention and thencloned. Clonal cultures can be used to produce human monoclonalantibodies, or the genetic elements encoding the variable portions ofthe heavy and light chain of the antibody can be cloned and insertedinto nucleic acid vectors for production of antibody of different types.

Antibody fragments are also encompassed by the invention. Well-knownfunctionally active antibody fragments include but are not limited toF(ab′)₂, Fab, Fv and Fd fragments of antibodies. These fragments whichlack the Fc fragment of intact antibody, clear more rapidly from thecirculation, and may have less non-specific tissue binding than anintact antibody (Wahl et al., J. Nucl. Med. 24:316-325 (1983)). Forexample, single-chain antibodies can be constructed in accordance withthe methods described in U.S. Pat. No. 4,946,778 to Ladner et al. Suchsingle-chain antibodies include the variable regions of the light andheavy chains joined by a flexible linker moiety. Methods for obtaining asingle domain antibody (“Fd”) which comprises an isolated variable heavychain single domain, also have been reported (see, for example, Ward etal., Nature 341:644-646 (1989), disclosing a method of screening toidentify an antibody heavy chain variable region (V_(H) single domainantibody) with sufficient affinity for its target epitope to bindthereto in isolated form). Methods for making recombinant Fv fragmentsbased on known antibody heavy chain and light chain variable regionsequences are known in the art and have been described, e.g., Moore etal., U.S. Pat. No. 4,462,334. Other references describing the use andgeneration of antibody fragments include e.g., Fab fragments (Tijssen,Practice and Theory of Enzyme Immunoassays (Elsevieer, Amsterdam,1985)), Fv fragments (Hochman et al., Biochemistry 12: 1130 (1973);Sharon et al., Biochemistry 15: 1591 (1976); Ehrilch et al., U.S. Pat.No. 4,355,023) and portions of antibody molecules (Audilore-Hargreaves,U.S. Pat. No. 4,470,925). Thus, those skilled in the art may constructantibody fragments from various portions of intact antibodies withoutdestroying the specificity of the antibodies.

Compositions and Pharmaceutical Preparations

The compositions of the invention, including for example theoligosaccharide-carrier conjugates of the invention, may be formulatedtogether with a pharmaceutically acceptable vehicle. The term“pharmaceutically-acceptable vehicle” as used herein means one or morecompatible solid or liquid filler, diluents or encapsulating substanceswhich are suitable for administration to a human or other animal. In thepresent invention, the term “vehicle” denotes an organic or inorganicingredient, natural or synthetic, with which the active ingredient iscombined to facilitate the application. The components of thepharmaceutical compositions also are capable of being commingled withthe conjugates, and with each other, in a manner such that there is nointeraction which would substantially impair the desired pharmaceuticalefficiency.

Thus, the composition of present invention may be regarded as apharmaceutical preparation. It may be used in vivo, but its use is notso limited. When used in vivo, it may be used in human or non-humansubjects, whether for therapeutic, prophylactic or research purposes. Asan example, the compositions may be used to generate antibodies and/orantibody producing cells in non-human subjects such as mice, rabbits,and other suitable animal hosts.

The invention therefore provides pharmaceutical preparations comprisingany of the foregoing oligosaccharide-carrier conjugates, which may beused as vaccines. These preparations may comprise the conjugates in anamount effective to stimulate an immune response, such as anantigen-specific immune response. These preparations may comprise otherconstituents or components such as but not limited to adjuvants andanti-bacterial agents. Such preparations may routinely containpharmaceutically acceptable concentrations of salt, buffering agents,preservatives, compatible carriers, adjuvants, and optionally othertherapeutic ingredients.

A suitable carrier media for formulating a vaccine includes sodiumphosphate-buffered saline (pH 7.4) or 0.125 M aluminum phosphate gelsuspended in sodium phosphate-buffered saline at pH 6 and otherconventional media. Generally, vaccines contain from about 5 to about100 μg, and preferably about 10-50 μg of the antigen to elicit effectivelevels of antibody in warm-blooded mammals.

An adjuvant is any substance which is incorporated into or administered(simultaneously or otherwise) with an antigen, which potentiates theimmune response to the antigen in the subject. Adjuvants include but arenot limited to aluminum compounds, e.g., gels, aluminum hydroxide andaluminum phosphate, and Freund's complete or incomplete adjuvant (e.g.,in which the antigen is incorporated in the aqueous phase of astabilized water in paraffin oil emulsion). The paraffin oil may bereplaced with different types of oils, e.g., squalene or peanut oil.Other materials with adjuvant properties include BCG (attenuatedMycobacterium tuberculosis), calcium phosphate, levamisole,isoprinosine, polyanions (e.g., poly A:U), lentinan, pertussis toxin,lipid A, saponins, QS-21 and peptides, e.g. muramyl dipeptide, andimmunostimulatory oligonucleotides such as CpG oligonucleotides. Rareearth salts, e.g., lanthanum and cerium, may also be used as adjuvants.The amount of adjuvants depends on the subject and the particularantigen used and can be readily determined by one skilled in the artwithout undue experimentation.

An anti-bacterial agent is an agent that kills bacteria (e.g., throughlysis) or prevents their division. The use of antibiotics in thetreatment of bacterial infection is routine. Anti-bacterial agentsinclude penicillin G, penicillin V, ampicillin, amoxicillin,bacampicillin, cyclacillin, epicillin, hetacillin, pivampicillin,methicillin, nafcillin, oxacillin, cloxacillin, dicloxacillin,flucloxacillin, carbenicillin, ticarcillin, avlocillin, mezlocillin,piperacillin, amdinocillin, cephalexin, cephradine, cefadoxil, cefaclor,cefazolin, cefuroxime axetil, cefamandole, cefonicid, cefoxitin,cefotaxime, ceftizoxime, cefinenoxine, ceftriaxone, moxalactam,cefotetan, cefoperazone, ceftazidme, imipenem, clavulanate, timentin,sulbactam, neomycin, erythromycin, metronidazole, chloramphenicol,clindamycin, lincomycin, vancomycin, trimethoprim-sulfamethoxazole,aminoglycosides, quinolones, tetracyclines and rifampin. (See Goodmanand Gilman's, Pharmacological Basics of Therapeutics, 8th Ed., 1993,McGraw Hill Inc.)

The conjugates may be attached covalently or non-covalently to othermoieties including but not limited to detectable labels such as imagingagents, fluorophores, enzymes, and the like.

Compositions suitable for parenteral administration convenientlycomprise a sterile aqueous preparation, which can be isotonic with theblood of the recipient. Among the acceptable vehicles and solvents thatmay be employed are water, Ringer's solution, and isotonic sodiumchloride solution. In addition, sterile, fixed oils are conventionallyemployed as a solvent or suspending medium. For this purpose any blandfixed oil may be employed including synthetic mono or di-glycerides. Inaddition, fatty acids such as oleic acid find use in the preparation ofinjectables. Carrier formulations suitable for subcutaneous,intramuscular, intraperitoneal, intravenous, etc. administrations may befound in Remington's Pharmaceutical Sciences, Mack Publishing Company,Easton, Pa.

The preparations of the invention are administered in effective amounts.An effective amount, as discussed above, in some instances is thatamount that will alone, or together with further doses, induce active orpassive immunity depending on the subject. It is believed that dosesranging from 1 nanogram/kilogram to 100 milligrams/kilogram, dependingupon the mode of administration, will be effective. The preferred rangeis believed to be between 500 nanograms and 500 micrograms/kilogram, andmost preferably between 1 microgram and 100 micrograms/kilogram. Theabsolute amount will depend upon a variety of factors including whetherthe administration is performed on a high risk subject not yet infectedwith the bacteria or on a subject already having an infection, theconcurrent treatment, the number of doses and the individual patientparameters including age, physical condition, size and weight. These arefactors well known to those of ordinary skill in the art and can beaddressed with no more than routine experimentation. It is preferredgenerally that a maximum dose be used, that is, the highest safe doseaccording to sound medical judgment.

Multiple doses of the compositions of the invention are contemplated.Generally immunization schemes involve the administration of a high doseof an antigen followed by subsequent lower doses of antigen after awaiting period of several weeks. Further doses may be administered aswell. The dosage schedule for passive immunization would be quitedifferent with more frequent administration if necessary. Any regimenthat results in an enhanced immune response to bacterial infectionand/or subsequent protection from infection may be used. Desired timeintervals for delivery of multiple doses of a particular conjugate canbe determined by one of ordinary skill in the art employing no more thanroutine experimentation.

A variety of administration routes are available. The particular modeselected will depend, of course, upon the particular conjugate selected,the particular condition being treated and the dosage required fortherapeutic efficacy. The methods of this invention, generally speaking,may be practiced using any mode of administration that is medicallyacceptable, meaning any mode that produces effective levels of an immuneresponse without causing clinically unacceptable adverse effects.Preferred modes of administration are parenteral routes. The term“parenteral” includes subcutaneous, intravenous, intramuscular,intraperitoneal, and intrasternal injection, or infusion techniques.Other routes include but are not limited to oral, nasal, dermal,sublingual, and local.

The following Examples are included for purposes of illustration and arenot intended to limit the scope of the invention.

EXAMPLES

Aspects of the invention are further illustrated by the followingnon-limiting Examples. These Examples illustrate inter alia how to makethe oligo-β-(1→6)-D-glucosamine oligosaccharides and how to conjugatesuch oligosaccharides to carriers such as protein carriers. Suchconjugates may be used, inter alia, as vaccines.

Example 1 Synthesis of N-hydroxysuccinimidyl 4-acetylsulfanylbutyrate 2

To a solution of the acid 1 (Hogg, J. Heather; Ollmann, Ian R.;Wetterholm, Anders; Andberg, Martina Blomster; Haeggstroem, Jesper; etal.; Chem. Europ. J.; EN; 4; 9; 1998; 1698-1713) (237 mg, 1.46 mmol) andN-hydroxysuccinimidyl trifluoroacetate (431 mg, 2.02 mmol) indichloromethane (4 mL) was added pyridine (355 μL, 4.4 mmol) and theresulting solution was stirred at room temperature for 2 h. The mixturewas diluted with dichloromethane (50 mL), and washed with ice-cold 1 MHCl and water, and concentrated. Silica gel column chromatography(toluene-ethyl acetate 9:1) of the residue gave the active ester 2 (359mg, 95%) as colorless syrup. ¹H NMR data (300 MHz, CDCl₃), δ 2.00 (m,2H, β-CH₂), 2.33 (s, 3H, CH₃COS), 2.68 (t, 2H, J=7.4 Hz, γ-CH₂), 2.81(s, 4H, 2 CH₂ of succinimide), 2.96 (t, 2H, J=7.1 Hz, α-CH₂). ¹³C NMRdata (62.9 MHZ, CDCl₃): δ 24.7 (β-CH₂), 25.6 (CH₂ of succinimide), 27.9(γ-CH₂), 29.7 (α-CH₂), 30.7 (CH₃COS), 168.0 (CO—ON), 169.2 (CO ofsuccinimide), 195.4 (CH₃COS).

Example 2 Synthesis of 4-nitrophenyl 4-acetylsulfanylbutyrate 3

To a solution of the acid 1 (233 mg, 1.44 mmol) (Hogg, J. Heather;Ollmann, Ian R.; Wetterholm, Anders; Andberg, Martina Blomster;Haeggstroem, Jesper; et al.; Chem. Europ. J.; EN; 4; 9; 1998; 1698-1713)and 4-nitrophenyl trifluoroacetate (470 mg, 2 mmol) in dichloromethanewas added triethylamine (400 μL, 2.88 mmol) and the solution was stirredfor 2 h at room temperature. The mixture was worked-up as described for2 and the active ester 3 (385 mg, 94%) was isolated by silica gel columnchromatography (toluene-ethyl acetate 92:8). ¹H NMR data (300 MHz,CDCl₃), δ 2.03 (m, 2H, β-CH₂), 2.36 (s, 3H, CH₃COS), 2.68 (t, 2H, J=7.2Hz, γ-CH₂), 3.01 (t, 2H, J=7.1 Hz, α-CH₂), 7.28, 8.26 (2 d, 4H,aromatics). ¹³C NMR data (62.9 MHZ, CDCl₃): δ 24.7 (β-CH₂), 28.0(γ-CH₂), 30.7 (CH₃COS), 32.7 (α-CH₂), 122.5, 125.2, 145.3, 155.3(aromatic C), 170.4 (COO), 195.5 (CH₃COS).

Example 3 Synthesis of the Ligands 6 and 7 Using Linking Reagent 2 or 3

Nonasaccharide 4 (M. L. Gening, Y. E. Tsvetkov, G. B. Pier, N. E.Nifantiev, <<Synthesis of oligo-β(1→6)-glucosamines corresponding to thefragments of the surface polysaccharide of Staphylococcus aureus>Carbohydr. Res. 342 (2007), 567-575) (110 mg, 0.023 mmol) was dissolvedin a mixture of MeOH (3 ml), THF (6 ml) and 1M HCl (0.2 ml) andPd(OH)₂/C (110 mg) was added. The resultant mixture was stirred underhydrogen atmosphere for 1 h. The catalyst was filtered off and thesolvents were evaporated. The residue was dissolved in a mixture ofCH₂Cl₂ (2 ml) and DMF (1 ml) and then linker reagent 2 (12 mg, 0.046mmol, solution in 1 ml of CH₂Cl₂) and Et₃N (100 μl) were added. After 30minutes the mixture was diluted with toluene, concentrated and subjectedto silica gel column chromatography (toluene/Me₂CO, 4:1) to give 5 (98mg, 98%) as a colorless foam. Introduction of the linker was confirmedby the presence of its characteristic signals in NMR spectra of theprotected carbohydrate ligand. ¹H NMR (500 MHz, CDCl₃): δ 1.88 (m, 2H,β-CH₂), 2.21 (t, 2H, J=7.2 Hz, γ-CH₂), 2.31 (s, 3H, CH₃COS), 2.88 (t,2H, J=7.1 Hz, α-CH₂). ¹³C NMR data (125 MHZ, CDCl₃): δ 25.7 (β-CH₂),28.5 (α-CH₂), 30.6 (CH₃COS), 35.1 (γ-CH₂).

A mixture of the protected nonasaccharide 5 (95 mg, 0.02 mmol), EtOH (5ml) and N₂H₄.H₂O (0.5 ml) was stirred under reflux for 1 h and thenconcentrated and subjected to gel permeation chromatography (TSK gelToyopearl HW 40S, 2.5×40 cm) in 0.1M aqueous AcOH to furnishnonasaccharide 6 (28 mg, 86%). Directly after gel chromatographySH-derivative may be obtained as it was detected by mass-spectrometry,but after storage in solution it converted to corresponding disulfide asit was confirmed by ¹³C NMR experiment. ¹H NMR (500 MHz, D₂O): δ 1.95(m, 2H, β-CH₂), 2.32 (t, 2H, J=7.2 Hz, γ-CH₂SH), 2.71 (t, 2H, J=7.1 Hz,α-CH₂). ¹³C NMR data (125 MHZ, D₂O): δ 29.7 (β-CH₂), 35.8 (γ-CH₂SH),38.5 (α-CH₂), 42.1 (γ-CH₂SS). Mass-spectra: calculated forC₆₁H₁₁₄N₁₀O₃₈S 543.234 [M+3H]³⁺, experimental 543.243 [M+3H]³⁺.

Nonasaccharide 6 (15 mg) was dissolved in a mixture of water/MeOH (2 ml,1:1 v/v) and dithiothreitol (15 mg) and NaHCO₃ (20 mg) were added. Theresultant mixture was stirred for 5 minutes and then acetic anhydride(100 μl) was added and stirring was continued for 30 minutes before thesolvents were evaporated. The product was purified by gel permeationchromatography (TSK gel Toyopearl HW 40S, 2.5×40 cm) in 0.1M aqueousAcOH to give acetylated product 7 (15 mg, 95%) ¹H-NMR (500 MHz, D₂O): δ1.75 (m, 2H, β-CH₂), 2.11 (t, 2H, J=7.2 Hz, γ-CH₂), 2.43 (s, 3H,CH₃COS), 2.75 (t, 2H, J=7.1 Hz, α-CH₂). ¹³C NMR data (125 MHZ, D₂O): δ25.7 (β-CH₂), 28.5 (α-CH₂), 30.6 (CH₃COS), 35.1 (γ-CH₂). Mass-spectra:calculated for C₈₁H₁₃₄N₁₀O₄₈S 1024.418 [M+2H]²⁺, experimental 1024.427[M+2H]²⁺

Example 4 Synthesis of the Protected Ligand 5 Using Linking Reagent 3

Nonasaccharide 4 (60 mg, 0.013 mmol) was dissolved in a mixture of MeOH(1.5 ml), THF (3 ml) and 1M HCl (0.1 ml) and Pd(OH)₂/C (60 mg) wasadded. The resultant mixture was stirred under hydrogen atmosphere for 1h. The catalyst was filtered off and the solvents were evaporated. Theresidue was dissolved in a mixture of CH₂Cl₂ (2 ml) and DMF (1 ml) andthen linker reagent 3 (20 mg, 0.07 mmol, solution in 1 ml of CH₂Cl₂) andEt₃N (50 μl) were added. After 20 h the mixture was diluted withtoluene, concentrated and subjected to silica gel column chromatography(toluene/Me₂CO, 4:1) to give 5 (37 mg, 68%) as a colorless foam.

Example 5 Study of Applicability of Linking Reagent 8 for thePreparation of Ligands for Further Conjugation with Protein

Pentasaccharide 9 (150 mg, 0.026 mmol) (M. L. Gening, Y. E. Tsvetkov, G.B. Pier, N. E. Nifantiev, <<Synthesis of oligo-β(1→6)-glucosaminescorresponding to the fragments of the surface polysaccharide ofStaphylococcus aureus>> Carbohydr. Res. 342 (2007), 567-575) wasdissolved in a mixture of MeOH (1.5 ml), THF (3 ml) and 1M HCl (0.1 ml)and Pd(OH)₂/C (150 mg) was added. The resultant mixture was stirredunder hydrogen atmosphere for 1 h. The catalyst was filtered off and thesolvents were evaporated. The residue was dissolved in a mixture ofCH₂Cl₂ (2 ml) and DMF (1 ml) and then linker reagent 8 (30 mg, 0.1 mmol,solution in 0.1 ml of CH₂Cl₂) and Et₃N (50 μl) were added. After 1 h themixture was diluted with toluene, concentrated and subjected to silicagel column chromatography (toluene/Me₂CO, 4:1) to give 10 (132 mg, 89%)as a colorless foam. ¹H NMR data (500 MHz, CDCl₃): δ 2.38 (s, 3H,CH₃COS), 3.53 (s, 2H, CH₂S); ¹³C NMR data (125 MHZ, CDCl₃): δ 30.2(CH₃COS), 32.9 (CH₂S).

A mixture of the protected pentasaccharide 10 (100 mg, 0.017 mmol), EtOH(5 ml) and N₂H₄.H₂O (0.5 ml) was stirred under reflux for 1 h and thenconcentrated and subjected to gel permeation chromatography (TSK gelToyopearl HW 40S, 2.5×40 cm) in 0.1M aqueous AcOH to furnishpentasaccharide 11 (32 mg, 93%). ¹H NMR data (500 MHz, D₂O): δ 7.17 (s,1H, CH═N); ¹³C NMR data (125 MHZ, D₂O): δ 134.6 (C═N—NH₂), 167.4(C(O)—CH═N). Mass-spectra: calculated for C₃₅H₆₇N₈O₂₂ 951.438 [M+H]⁺,experimental 951.448 [M+H]⁺.

Example 6 Study of Applicability of Linking Reagent 12 for thePreparation of Ligands for Further Conjugation with Protein

Pentasaccharide 9 (100 mg, 0.017 mmol) (M. L. Gening, Y. E. Tsvetkov, G.B. Pier, N. E. Nifantiev, <<Synthesis of oligo-β(1→6)-glucosaminescorresponding to the fragments of the surface polysaccharide ofStaphylococcus aureus>> Carbohydr. Res. 342 (2007), 567-575) wasdissolved in a mixture of MeOH (1.5 ml), THF (3 ml) and 1M HCl (0.1 ml)and Pd(OH)₂/C (150 mg) was added. The resultant mixture was stirredunder hydrogen atmosphere for 1 h. The catalyst was filtered off and thesolvents were evaporated. The residue was dissolved in a mixture ofCH₂Cl₂ (2 ml) and DMF (1 ml) and then linker reagent 12 (15 mg, 0.061mmol, solution in 0.1 ml of CH₂Cl₂) and Et₃N (50 μl) were added. After 1h the mixture was diluted with toluene, concentrated and subjected tosilica gel column chromatography (toluene/Me₂CO, 4:1) to give 13 (87 mg,85%) as a colorless foam. ¹H NMR data (500 MHz, CDCl₃): δ 2.33 (s, 3H,CH₃COS), 2.52 (m, 2H, COCH₂), 3.15 (t, 2H, J7.6, CH₂S); ¹³C NMR data(125 MHZ, CDCl₃): δ 25.2 (CH₃COS), 29.2 (COCH₂), 35.9 (CH₂S).

A mixture of the protected pentasaccharide 13 (80 mg, 0.015 mmol), EtOH(5 ml) and N₂H₄.H₂O (0.5 ml) was stirred under reflux for 1 h and thenconcentrated and subjected to gel permeation chromatography (TSK gelToyopearl HW 40S, 2.5×40 cm) in 0.1M aqueous AcOH to give complexmixture of nonidentified products.

Example 7 Preparation of the conjugate of tetanus toxoid with ligand6-“TT-9NH₂”

Step 1. Protein Modification.

Tetanus toxoid (4 mg in 120 stock solution) was diluted with 400 μl ofpH 7.2 buffer (0.1 M sodium phosphate, 0.15 M NaCl, 10 mM EDTA), thesolution of SBAP (2.6 mg) in DMSO (80 μl) was added and the mixture wasincubated for 2 h at RT. Unreacted SBAP was removed using PD-10 columnin pH 8.0 running buffer (0.1 M sodium phosphate, 0.15 M NaCl, 10 mMEDTA) and resultant 3.5 ml solution of modified protein was concentratedto 400 μl.

Step 2. Disulfide Reduction.

Immobilized TCEP Disulfide Reducing Gel (200 μl of 50% slurry in water)was centrifuged, an excess of water was removed and disulfide 6 (1.5 mgin 100 μl of pH 8.0 buffer (0.1 M sodium phosphate, 0.15 M NaCl, 10 mMEDTA)) was added. After incubation on a rotor rack at room temperaturefor 45 min, the solution of SH-derivative was separated from the gel bycentrifugation and immobilized TCEP was washed with the same pH 8.0buffer (3×100 μl).

Step 3. Conjugation.

The solution of the ligand obtained in Step 2 (400 μl in pH 8.0 buffer)was immediately combined with modified protein (400 μl in pH 8.0 buffer,Step 1.) and stirred overnight at room temperature. After this time, theconjugate was separated from uncoupled components by gel filtration onSuperose 6 prep-grade column. Fractions, containing TT-9NH₂ conjugatewere pooled, concentrated and stored frozen at −20° C.

Chemical Analysis of Conjugate.

Conjugate was analyzed for its contents of oligosaccharides usinghexosamine assay described by Smith and Gilkerson (R. L. Smith and E.Gilkerson. 1979 Analytical Biochem. 98: 478-480) with compounds 6 as astandard and for protein with the Bradford assay (M. M. Bradford, 1976,Analytical Biochem. 72:248-254). According to these assays, conjugateTT-9NH₂ contains 74 carbohydrate ligands per protein molecule (x=74).

Example 8 Preparation of the Conjugate of Tetanus Toxoid with Ligand7-“TT-9NAc”

Step 1. Protein Modification.

TT was modified with SBAP as described above for conjugate TT-9NH₂.

Step 2. 5-Acetyl Deprotection.

Nonasaccharide 7 (2.1 mg) was dissolved in 200 μl of 7% aqueous NH₃solution, the mixture was kept at room temperature for 1 hour and thenlyophilized.

Step 3. Conjugation.

Lyophilized oligosaccharide was immediately dissolved in 400 μl of pH8.0 buffer (0.1 M sodium phosphate, 0.15 M NaCl, 10 mM EDTA) and mixedwith 400 μl of TT-modified solution in the same buffer. Reaction mixturewas stirred overnight at room temperature. After this time, theconjugate was separated from uncoupled components by gel filtration onSuperose 6 prep-grade column. Fractions containing TT-9NAc conjugatewere pooled, concentrated and stored frozen at −20° C.

Chemical Analysis of Conjugate.

The analysis was performed the same way as for conjugate TT-9NH₂(Example 7) and revealed that conjugate TT-9NAc contains 71 carbohydrateligands per protein molecule (y=71).

Example 9 Antibody Production Using Oligosaccharide Conjugates

Methods.

Rabbits were immunized subcutaneously with 10 μg polysaccharideequivalent of nonaglucosamine (i.e., 9 linked monomers) conjugated totetanus toxoid (TT) twice, one week apart, with an equivalent volume ofSpecol adjuvant. On the third week, rabbits were immunized three times(i.e., on Monday, Wednesday and Friday) with 10 μg PS-equivalent IV insaline. After the last immunization, rabbits were rested for two weeksand blood was taken every two weeks. Data in this presentationincorporate results from the first (bleed 1) and second (bleed 2) seraobtained post-immunization

Results.

FIGS. 1A and B show the data relating to binding of antisera raised tonon-acetylated nona-glucosamine (9GlcNH₂) to PNAG (A) or dPNAG (B) fromS. aureus. dPNAG used in this experiment was about 15% acetylated.However, it is to be understood that the level of acetylation may rangefrom 0-40%. The data show that the antisera bound comparably to bothPNAG and dPNAG.

FIGS. 2A and B show the data relating to binding of antisera raise tofully acetylated non-glucosamine (9GlcNAc) to PNAG or dPNAG from S.aureus. The data show that the antisera bound better to highlyacetylated PNAG than to dPNAG.

FIGS. 3A and B show the data relating to the binding of antisera raisedto TT-conjugated 9GlcNAc or 9GlcNH₂ to unconjugated 11 GlcNAc or11GlcNH₂. The data show that the antiserum raised against acetylated9GlcNAc bound better to acetylated 11GlcNAc than did the antiserumraised against non-acetylated 9GlcNH₂. The opposite was true for bindingto 9GlcNH₂, as antisera to 9GlcNH₂-TT conjugate was off-scale at serumdilutions of less than 6400.

FIGS. 4 and 5 show results using antisera from bleed 1 against S. aureusMN8 and two USA300 strains. FIG. 4 compares the killing of S. aureus MN8(CP8) by rabbit antisera (referred to as “bleed 1”) to fully acetylatedor non-acetylated 9-mer oligoglucosamine conjugated to tetanus toxoid(TT). FIG. 5 compares the killing of S. aureus MN8 by rabbit antisera(bleed 1) to fully acetylated or non-acetylated 9-mer oligoglucosamineconjugated to TT. Anti-dPNAG-TT conjugate antiserum was used as acomparator. FIG. 6 compares the killing of S. aureus LAC(NT, USA300) byrabbit sera (bleed 1) to fully acetylated or non-acetylated 9-meroligoglucosamine conjugated to TT. FIG. 7 compares the killing of S.aureus SF8300 (NT, USA300) by rabbit sera (bleed 1) to fully acetylatedor non-acetylated 9-mer oligoglucosamine conjugated to TT. FIG. 8compares the killing of S. aureus LAC(NT, USA300) by rabbit sera(bleed 1) to fully acetylated or non-acetylated 9-mer oligoglucosamineconjugated to TT. In general, serum raised to 9GlcNH₂-TT demonstratedthe best overall activity but in most assays was only slightly betterthan serum raised to 9GIcNAc-TT.

FIGS. 9-16 show killing data resulting from the use of bleed 2 sera.Rabbit anti dPNAG-TT control used as comparator for strains MN8, SF8300and LAC. Goat anti-dPNAG-TT was used as a comparator for Newman (CP5),PS80 (CP8) and the isogenic strains Reynolds CP5, Reynolds non-typableand Reynolds CP8.

FIG. 9 compares the killing of S. aureus MN8 (CP8) by rabbit sera (bleed2) to fully acetylated or non-acetylated 9-mer oligoglucosamineconjugated to TT. FIG. 10 compares the killing of S. aureus LAC(NT.USA300) by rabbit sera (bleed 2) to fully acetylated or non-acetylated9-mer oligoglucosamine conjugated to TT. FIG. 11 compares the killing ofS. aureus SF8300 (NT, USA300) by rabbit sera (bleed 2) to fullyacetylated or non-acetylated 9-mer oligoglucosamine conjugated to TT.FIG. 12 compares the killing of S. aureus Newman (CP5) by rabbit sera(bleed 2) to fully acetylated or non-acetylated 9-mer oligoglucosamineconjugated to TT. FIG. 13 compares the killing of S. aureus PS80 byrabbit sera (bleed 2) to fully acetylated or non-acetylated 9-meroligoglucosamine conjugated to TT. FIG. 14 compares the killing of S.aureus Reynolds (CP5) by rabbit sera (bleed 2) to fully acetylated ornon-acetylated 9-mer oligoglucosamine conjugated to TT. FIG. 15 comparesthe killing of S. aureus Reynolds (non-typable) by rabbit sera (bleed 2)to fully acetylated or non-acetylated 9-mer oligoglucosamine conjugatedto TT. FIG. 16 compares the killing of S. aureus Reynolds (CP8) byrabbit sera (bleed 2) to fully acetylated or non-acetylated 9-meroligoglucosamine conjugated to TT.

Generally, a higher degree of killing was achieved using antisera raisedto the oligosaccharide conjugates than with antiserum raised todPNAG-TT. Killing of strains LAC and SF8300 was better with bleed 2 seraas compared with bleed 1 sera even though the ELISA binding curves aresimilar. Using bleed 2, a greater difference in killing using theantisera raised to 9GlcNH₂ is seen as compared to lysis using serumraised to 9GlcNAc.

Example 10 Rabbit Antisera and Opsonic Killing of E. coli

Rabbit antibodies in post-immunization rabbit antisera (as describedabove) mediated opsonic killing of two E. coli strains previously shownto produce PNAG, but not a third strain lacking the pga genes encodingthe biosynthetic enzymes for PNAG in E. coli (FIG. 16A).

Example 11 Mouse Skin Abscess Models

FIGS. 17, 18 and 19 show the results of an in vivo study using a mouseskin abscess model and challenge with S. aureus strain LAC (USA300).Antisera raised to 9GlcNH₂ demonstrated protective efficacy against anS. aureus LAC (USA300) skin infection. Group 1 (labeled 9GlcNH₂-TT) wasadministered 0.2 ml of 9GlcNH₂-TT antiserum (bleed 2) intraperitoneally24 hours prior to infection. Group 2 (labeled NRS) was administered 0.2ml of normal rabbit serum (NRS) 24 hours prior to infection. Mice wereinfected with 2×10⁴ CFU (FIG. 17), 2×10⁵ CFU (FIG. 19), or 2×10⁶ CFU(FIG. 20) in a 100 μl subcutaneous injection (per abscess) with microdexbeads (10 g/ml). S. aureus LAC strain was grown in TSB overnight, thenwashed and added to the microdex beads prior to administration. After 72hours, each abscess was excised, resuspended in 1 ml of TSB,homogenized, diluted, and then 100 μl of homogenate were plated alongwith serial dilutions. The lower limit of detection was 10 CFU/abscess.FIGS. 17, 18 and 19 show that the number of CFU per abscess was greatlyreduced in mice administered the 9GlcNH₂-TT antiserum as compared to thenormal rabbit serum. FIG. 20 summarizes the results of FIGS. 18-20showing that at every dose of S. aureus, the mice administered 9GlcNH₂were better protected against the S. aureus challenge.

FIGS. 21 and 22 show the results of two in vivo studies using the samemouse skin abscess model and procedures described in the precedingparagraph but the challenge strains are two additional S. aureusstrains, MN8 and Newman. Mice were infected with 1×10⁶ CFU of strain MN8(FIG. 21) or 4×10⁶ CFU of strain Newman (FIG. 22) in a 100 μlsubcutaneous injection (per abscess) with microdex beads (10 g/ml).FIGS. 21 and 22 show that the number of CFU per abscess wassignificantly reduced in mice administered the 9GleNH₂-TT antiserum ascompared to the normal rabbit serum.

FIG. 23 shows the inability of the antiserum raised to the 9GleNH₂-TTconjugate vaccine to significantly (P>0.05) reduce the CFU/abscess of S.aureus strains MN8Δica and NewmanΔica. These two strains have had theica genetic locus removed and can no longer synthesize the PNAG surfacepolysaccharide. In the absence of the PNAG antigen, the antibody to the9GlcNH₂ oligosaccharide cannot provide any protective immunity to S.aureus skin infections.

Example 12 Protective Efficacy Against E. coli Peritonitis

The protective efficacy of antibody to 9GlcNH₂-TT was tested in a lethalperitonitis model of E. coli infection. This antibody protected allimmunized mice against infection caused by two PNAG-positive E. coliisolates (Table 1, UTI strains J and P) whereas all controls receivingNRS did not survive. There was no protection afforded by antibody to9GlcNH₂-TT antiserum against PNAG-negative E. coli strain H.

TABLE 1 Protective efficacy of antibody to 9GlcNH₂-TT against lethalperitonitis caused by E. coli. Number of survivors Challenge out oftotal mice P value E. coli strain Anti-9GlcNH₂TT NRS^(a) (Fisher's exacttest) J (PNAG⁺) 8/8 0/8 0.0002 P (PNAG⁺) 8/8 0/8 0.0002 H (PNAG⁻⁾ 0/80/8 1.0 ^(a)NRS: normal rabbit serum

Discussion of Results

Using the fully non-acetylated, synthetic GlcNH₂-TT conjugate vaccines,it has been found according to the invention that no acetates arerequired for generating high levels of opsonic and protective antibodiesin animals, that conjugating a molecule as small as five GlcNH₂-monomersin size is sufficient for a robust immune response, and that theseantibodies readily bind to highly N-acetylated PNAG, poorly acetylateddPNAG and the non-acetylated oligosaccharides. These protectiveantibodies will therefore bind to naturally occurring PNAG regardless ofits composition, including its level of acetylation.

The invention further contemplates producing vaccines that comprisemultiple antigens including the non-acetylated oligosaccharides of theinvention. The synthesis of GlcNH₂-oligomers with a reducing end linkercontaining a reactive sulfhydryl group suggests that vaccines targetingmicrobes that make PNAG could be made more effective by conjugating theGlcNH₂-oligosaccharides to microbial proteins that function as virulencefactors and vaccine antigens. For example, the LcrV protein of Y. pestisis a target for protection against plague (Garmory et al. Vaccine22:947-57 (2004); Overheim et al. Infect. Immun. 73:5152-9 (2005);Quenee et al. Infect. Immun. 76:2025-2036 (2008)) but serologic variantsof this protein are known among strains of Y. pestis circulating incentral Asia (Anisimov et al. Clin. Microbiol. Rev. 17:434-64 (2004)),making it possible such strains could evade immunity engendered by asingle LcrV vaccine component. As PNAG is expressed by Y. pestis,conjugating GlcNH₂-oligomers to LcrV might enhance the protectivecoverage of a plague vaccine. This approach to vaccine production isattractive since the synthetic version of dPNAG oligosaccharides can beproduced fairly inexpensively and, importantly, will not have any othermicrobial contaminants.

Overall these findings indicate that small sized oligomers ofbeta(1→6)-linked glucosamine conjugated to a carrier protein can inducehigh titers of opsonic antibody that is also protective againstexperimental S. aureus skin infection and lethal peritonitis due to E.coli.

EQUIVALENTS

While several inventive embodiments have been described and illustratedherein, those of ordinary skill in the art will readily envision avariety of other means and/or structures for performing the functionand/or obtaining the results and/or one or more of the advantagesdescribed herein, and each of such variations and/or modifications isdeemed to be within the scope of the inventive embodiments describedherein. More generally, those skilled in the art will readily appreciatethat all parameters, dimensions, materials, and configurations describedherein are meant to be exemplary and that the actual parameters,dimensions, materials, and/or configurations will depend upon thespecific application or applications for which the inventive teachingsis/are used. Those skilled in the art will recognize, or be able toascertain using no more than routine experimentation, many equivalentsto the specific inventive embodiments described herein. It is,therefore, to be understood that the foregoing embodiments are presentedby way of example only and that, within the scope of the appended claimsand equivalents thereto, inventive embodiments may be practicedotherwise than as specifically described and claimed. Inventiveembodiments of the present disclosure are directed to each individualfeature, system, article, material, kit, and/or method described herein.In addition, any combination of two or more such features, systems,articles, materials, kits, and/or methods, if such features, systems,articles, materials, kits, and/or methods are not mutually inconsistent,is included within the inventive scope of the present disclosure.

All definitions, as defined and used herein, should be understood tocontrol over dictionary definitions, definitions in documentsincorporated by reference, and/or ordinary meanings of the definedterms.

All references, patents and patent applications disclosed herein areincorporated by reference with respect to the subject matter for whicheach is cited, which in some cases may encompass the entirety of thedocument.

The indefinite articles “a” and “an,” as used herein in thespecification and in the claims, unless clearly indicated to thecontrary, should be understood to mean “at least one.”

The phrase “and/or,” as used herein in the specification and in theclaims, should be understood to mean “either or both” of the elements soconjoined, i.e., elements that are conjunctively present in some casesand disjunctively present in other cases. Multiple elements listed with“and/or” should be construed in the same fashion, i.e., “one or more” ofthe elements so conjoined. Other elements may optionally be presentother than the elements specifically identified by the “and/or” clause,whether related or unrelated to those elements specifically identified.Thus, as a non-limiting example, a reference to “A and/or B”, when usedin conjunction with open-ended language such as “comprising” can refer,in one embodiment, to A only (optionally including elements other thanB); in another embodiment, to B only (optionally including elementsother than A); in yet another embodiment, to both A and B (optionallyincluding other elements); etc.

As used herein in the specification and in the claims, “or” should beunderstood to have the same meaning as “and/or” as defined above. Forexample, when separating items in a list, “or” or “and/or” shall beinterpreted as being inclusive, i.e., the inclusion of at least one, butalso including more than one, of a number or list of elements, and,optionally, additional unlisted items. Only terms clearly indicated tothe contrary, such as “only one of” or “exactly one of,” or, when usedin the claims, “consisting of,” will refer to the inclusion of exactlyone element of a number or list of elements. In general, the term “or”as used herein shall only be interpreted as indicating exclusivealternatives (i.e. “one or the other but not both”) when preceded byterms of exclusivity, such as “either,” “one of,” “only one of,” or“exactly one of.” “Consisting essentially of,” when used in the claims,shall have its ordinary meaning as used in the field of patent law.

As used herein in the specification and in the claims, the phrase “atleast one,” in reference to a list of one or more elements, should beunderstood to mean at least one element selected from any one or more ofthe elements in the list of elements, but not necessarily including atleast one of each and every element specifically listed within the listof elements and not excluding any combinations of elements in the listof elements. This definition also allows that elements may optionally bepresent other than the elements specifically identified within the listof elements to which the phrase “at least one” refers, whether relatedor unrelated to those elements specifically identified. Thus, as anon-limiting example, “at least one of A and B” (or, equivalently, “atleast one of A or B,” or, equivalently “at least one of A and/or B”) canrefer, in one embodiment, to at least one, optionally including morethan one, A, with no B present (and optionally including elements otherthan B); in another embodiment, to at least one, optionally includingmore than one, B, with no A present (and optionally including elementsother than A); in yet another embodiment, to at least one, optionallyincluding more than one, A, and at least one, optionally including morethan one, B (and optionally including other elements); etc.

It should also be understood that, unless clearly indicated to thecontrary, in any methods claimed herein that include more than one stepor act, the order of the steps or acts of the method is not necessarilylimited to the order in which the steps or acts of the method arerecited.

In the claims, as well as in the specification above, all transitionalphrases such as “comprising,” “including,” “carrying,” “having,”“containing,” “involving,” “holding,” “composed of,” and the like are tobe understood to be open-ended, i.e., to mean including but not limitedto. Only the transitional phrases “consisting of” and “consistingessentially of” shall be closed or semi-closed transitional phrases,respectively, as set forth in the United States Patent Office Manual ofPatent Examining Procedures, Section 2111.03.

What is claimed is: 1-30. (canceled)
 31. A method for synthesizing anoligosaccharide-carrier conjugate comprising reacting an oligosaccharideconjugated to a linker of Formula IXa or IXb

with a carrier having modified amino group following reaction with acompound of Formula

to yield an oligosaccharide conjugated to a carrier compound through alinker having a structure of Formula VIIIa or VIIIb. 32-40. (canceled)41. A method for stimulating an immune response in a subject comprisingadministering to a subject in need thereof an oligosaccharide-carrierconjugate comprising an oligosaccharide conjugated to a carrier througha linker that is

wherein the linker is O-linked to the oligosaccharide and N-linked tothe carrier in an amount effective to stimulate an immune response inthe subject.
 42. The method of claim 41, wherein the subject is a human.43. The method of claim 41, wherein the subject is non-human.
 44. Themethod of claim 41, further comprising isolating antibodies orantibody-forming cells from the subject.
 45. The method of claim 41,further comprising administering an adjuvant to the subject.
 46. Themethod of claim 41, further comprising administering an anti-bacterialagent to the subject.
 47. A method for treating or preventing aninfection in a subject comprising administering to a subject having orat risk of developing an infection an effective amount for inducing animmune response of an oligosaccharide-carrier conjugate comprising anoligosaccharide conjugated to a carrier through a linker that is

wherein the linker is O-linked to the oligosaccharide and N-linked tothe carrier, wherein the infection is caused by a bacterial species thatproduces PNAG.
 48. The method of claim 47, wherein the infection is aStaphylococcus infection.
 49. The method of claim 47, wherein theStaphylococcus infection is Staphylococcus aureus infection.
 50. Themethod of claim 47, wherein the Staphylococcus infection isStaphylococcus epidermidis.
 51. The method of claim 47, wherein thesubject is at risk of exposure to Staphylococcus.
 52. The method ofclaim 47, wherein the subject has been exposed to Staphylococcus. 53.The method of claim 47, wherein the infection is an E. coli infection, aY. pestis infection, a Y. entercolitica infection, a Y.pseudotuberculosis infection, an Aggregatibacter actinomycetemcomitansinfection, an Actinobacillus pleuropneumoniae infection, a Bordetellapertussis infection, a B. parapertussis infection, a B. bronchisepticainfection, an Acinetobacter infection, a Burkholderia infection, aStenatrophomonas maltophilia infection, a Shigella infection, or aKlebsiella infection.
 54. The method of claim 47, wherein theoligosaccharide-carrier conjugate is administered with an adjuvant. 55.A method for producing antibodies comprising: administering to a subjectan effective amount, for producing antibodies specific for PNAG, of anoligosaccharide-carrier conjugate comprising an oligosaccharideconjugated to a carrier through a linker that is

wherein the linker is O-linked to the oligosaccharide and N-linked tothe carrier, and isolating antibodies from the subject.
 56. A method forproducing monoclonal antibodies comprising: administering to a subjectan effective amount, for producing antibodies specific for PNAG, of anoligosaccharide-carrier conjugate comprising an oligosaccharideconjugated to a carrier through a linker that is

wherein the linker is O-linked to the oligosaccharide and N-linked tothe carrier, harvesting antibody-producing cells from the subject,fusing antibody-producing cells from the subject to myeloma cells, andharvesting antibody produced from a fusion subclone.
 57. The method ofclaim 55, wherein the antibodies are polyclonal antibodies.
 58. Themethod of claim 55, wherein the subject is a rabbit.
 59. The method ofclaim 55, wherein the subject is human.